ClinicalTrials.gg
CompletedNCT00071188Updated Aug 25, 2016

ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of ZD6474 and Paclitaxel in Carcinoma, Non-Small-Cell Lung, sponsored by Genzyme, a Sanofi Company. Completed at 34 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-25.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 24 studies testing vandetanib in Carcinoma, Non-Small-Cell Lung — none open to participants now, none under way, none of them phase 3. vandetanib · Carcinoma, Non-Small-Cell Lung.

Started
2004
with 1 other
Phase 2
12 of 24
none open now
Registered
3rd of 24
by date
Lead sponsor
12 of 24
Genzyme, a Sanofi Company

Among the 24 studies testing vandetanib in Carcinoma, Non-Small-Cell Lung, this one is one of 2 that started in 2004, is one of 12 in phase 2, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 24 studies testing vandetanib in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

About vandetanib

vandetanib: first FDA approval 2011 (CAPRELSA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing vandetanib in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

The purpose of the run-in phase of this study is to determine the appropriate and tolerable dose of ZD6474 (200mg or 300mg) to be administered in combination with paclitaxel and carboplatin in subjects with previously untreated locally advanced or metastatic NSCLC. This phase of the trial is closed to enrollment.

The purpose of the randomized phase of this study is to determine the efficacy of ZD6474 alone versus that of ZD6474 in combination with paclitaxel and carboplatin versus that of paclitaxel and carboplatin alone in subjects with previously untreated locally advanced or metastatic NSCLC. This phase of the trial is closed to enrollment.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Non-Small-Cell Lung Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • 18 years or older
  • or cytologically confirmed locally advanced or NSCLC
  • No prior chemotherapy/biological therapy/radiation therapy
  • One or more
  • more than 12 weeks

Exclusion criteria

Exclusion Criteria:

  • or spinal cord compression
  • Currently active skin disease
  • History of significant hemoptysis
  • Abnormal blood chemistry
  • Cardiac abnormalities
  • Recent significant cardiac event
  • Coexisting
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)

Interventions

06

Study locations

34 sites
  • Research Site
    Concord, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Boston, Massachusetts, United States
  • Research Site
    St. Louis, Missouri, United States
  • Research Site
    Providence, Rhode Island, United States
  • Research Site
    Nashville, Tennessee, United States
  • Research Site
    Austin, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Lubbock, Texas, United States
  • Research Site
    Norfolk, Virginia, United States
  • Research Site
    Seattle, Washington, United States
  • Research Site
    Helsinki, Finland
  • Research Site
    Turku, Finland
  • Research Site
    Besancon, France
  • Research Site
    Lille, France
  • Research Site
    Strasbourg, France
  • Research Site
    Essen, Germany
  • Research Site
    Frankfurt, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    Ulm, Germany
  • Research Site
    Pune, India
  • Research Site
    Milano, Italy
  • Research Site
    Orbassano, Italy
  • Research Site
    Cape Town, South Africa
  • Research Site
    Johannesburg, South Africa
  • Research Site
    Panorama, South Africa
  • Research Site
    Parkland, South Africa
  • Research Site
    Pretoria, South Africa
  • Research Site
    Barcelona, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Malaga, Spain
  • Research Site
    Pamplona, Spain
  • Research Site
    Chiang mai, Thailand
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2004, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2003
First posted
Oct 16, 2003
Start
Feb 2004
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Last update
Aug 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00071188
Responsible party
Sponsor
First posted
Oct 16, 2003
Start date
Feb 2004
Primary completion
Oct 2007
Completion
Oct 2007
Last update
Aug 25, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vandetanib · Paclitaxel · Carboplatin

Start the discussion